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Abstract
OBJECTIVES—The goal of this study was to determine whether subclinical thyroid dysfunction
was associated with incident heart failure (HF) and echocardiogram abnormalities.
BACKGROUND—Subclinical hypothyroidism and hyperthyroidism have been associated with
cardiac dysfunction. However, long-term data on the risk of HF are limited.
METHODS—We studied 3044 adults ≥65 years initially free of HF in the Cardiovascular Health
Study (CHS). We compared adjudicated HF events over a mean 12-year follow-up and changes in
cardiac function over 5 years among euthyroid participants, those with subclinical hypothyroidism
(subdivided by TSH levels: 4.5–9.9, ≥10.0 mU/L), and those with subclinical hyperthyroidism.
RESULTS—Over 12 years, 736 participants developed HF events. Participants with TSH≥10.0 mU/
L had a greater incidence of HF compared to euthyroid participants (41.7 vs. 22.9/1000 person years,
p=0.01, adjusted hazard ratio=1.88, 95% confidence interval 1.05–3.34). Baseline peak E velocity,
an echocardiographic measurement of diastolic function associated with incident HF in the CHS
cohort, was higher in those with TSH≥10.0 compared to euthyroid participants (0.80 vs. 0.72 m/sec,
p=0.002). Over 5 years, left ventricular mass increased among those with TSH≥10.0, but other
echocardiographic measurements were unchanged. Those with TSH 4.5–9.9 or with subclinical
hyperthyroidism had no increase in risk of HF.
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CONCLUSIONS—Compared to euthyroid older adults, those with a TSH≥10.0 mU/L have a
moderately elevated risk of HF and alterations in cardiac function, but not older adults with TSH<10.
Clinical trials should assess whether the risk of HF might be ameliorated by thyroxine replacement
in individuals with TSH≥10.0 mU/L.
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Subclinical thyroid dysfunction is present in patients who have an abnormal thyrotropin
(thyroid-stimulating hormone, TSH) level and a normal free thyroxine (FT4) level(1).
Subclinical thyroid dysfunction is common, particularly in older individuals, with a prevalence
of subclinical hypothyroidism of 10% and subclinical hyperthyroidism of 1.5%(2,3). Whereas
it is generally accepted to treat the abnormal free thyroxine levels of overt thyroid dysfunction,
the indications and threshold TSH for treatment of subclinical hypothyroidism and subclinical
hyperthyroidism are areas of clinical controversy(1,3,4), as current evidence about the risks is
limited(1,3).
Based on the known effects of thyroid hormone on the heart, it is reasonable to expect adverse
cardiac effects in subclinical thyroid dysfunction(5). Subclinical thyroid disease has been
associated with systolic and diastolic cardiac dysfunction, and small studies have shown that
thyroxine replacement improved measurements of cardiac function in subjects with subclinical
hypothyroidism(6,7). However, the clinical importance of these effects is unclear(3,8). Data
on cardiovascular risks are conflicting(9–11), and no randomized clinical trials (RCT) have
assessed the impact of thyroxine replacement on clinical cardiac endpoints(3). Only one study
has examined the relationship between subclinical thyroid dysfunction and HF events. In a
population-based study of adults aged 70–79, participants with TSH≥7.0 mU/L had a more
than 2-fold higher risk of HF events, compared to euthyroid subjects(10), but echocardiography
was not performed. No study has directly addressed the relationship between subclinical
hyperthyroidism and HF events.
As the number of hospitalizations for HF has greatly increased(12), examining a common and
easily treatable potential risk factor for HF is warranted. To determine whether subclinical
thyroid dysfunction was associated with HF and cardiac dysfunction, we examined a large
cohort study of community-dwelling older adults.
Methods
Study Population
Participants were part of the Cardiovascular Health Study (CHS), a population-based,
longitudinal study of risk factors for the development of cardiovascular disease (CVD) in 5888
adults ≥65 years(13). Enrolment of an original cohort of 5201 adults occurred in 1989–1990,
and an additional cohort of 687, predominantly African Americans, was enrolled in 1992–
1993. Eligible individuals were identified from an age- and sex-stratified random sample of
the Medicare-eligible adults in 4 US communities. Details of the eligibility criteria have been
previously described(9). All participants gave written informed consent; the Institutional
Review Boards at study sites approved the protocol.
Fasting TSH was measured at baseline in a subsample (n=3678) of CHS participants, selected
according to availability of stored serum for analysis. Because our primary study question
pertained to unrecognized thyroid function abnormalities, participants taking thyroid hormone
preparations at baseline (n=339) or other medications that could affect thyroid testing,
including antithyroid drugs (n=1), corticosteroids (n=77) and amiodarone (n=2), were
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excluded. We also excluded participants with known HF at baseline (n=144) to examine
incident HF.
Measurements
Thyroid Hormones—Serum TSH and FT4 concentrations were assayed, as previously
described(9), with FT4 (normal range: 0.7–1.7 ng/dL [9–22 pmol/L]) measured in individuals
with TSH <0.10 or >4.50 mU/L for the 95% of samples with sufficient serum for this additional
test. Compared to those without thyroid function testing (n=1523), participants with thyroid
function testing were less likely to be men (38 vs. 55%, p<0.001) and to have prevalent CVD
(22 vs. 26%, p=0.002), but mean ages, race proportions, thyroxine use, and prevalent HF were
similar.
Study participants were classified into 3 groups based on their thyroid function tests(9):
1. Subclinical hyperthyroidism: TSH≥0.10 and <0.45 mU/L(3) (n=38), or <0.10 with a
normal FT4 (n=6).
2. Euthyroidism: normal TSH (0.45–4.50 mU/L) (n=2526).
3. Subclinical hypothyroidism: TSH>4.50 and <20 mU/L with a normal FT4 (n=474).
Based upon the definitions used by the United States Preventive Services Task Force
(USPSTF)(1) and on expert consensus(3), subclinical hypothyroidism was
subclassified according to TSH levels: 4.5–9.9 (n=428), and ≥10 (marked elevation,
n=46), because of possible higher risks above this cut-off. In additional analyses, mild
subclinical hypothyroidism was further subclassified between those with TSH 4.5–
6.9 (mild elevation, n=337) and 7.0–9.9 (moderate elevation, n=91), based upon
USPSTF definitions(1).
Participants whose testing suggested nonthyroidal illness (low TSH and FT4, n=2), ≥TSH 4.50
and a missing FT4 (n=21), and overt thyrotoxicosis (TSH<0.10 with an elevated FT4, n=1) or
overt hypothyroidism (TSH≥20 mU/L or >4.50 with a FT4<0.70 ng/dL, n=47) were excluded
from analyses. The sample for our analyses was 3044.
HF events—During the 15-year follow-up, we assessed incident HF events among
participants free of HF at baseline. Clinical outcomes were ascertained every six months.
Diagnoses have been adjudicated until 6/30/2004 based on interview, review of medical
records, and other support documents without knowledge of thyroid status. HF events were
defined on the basis of diagnosis from a physician and consideration of symptoms, signs, chest
radiographs, and treatment of heart failure (current prescription for a diuretic agent and digitalis
or a vasodilator)(14,15).
Echocardiography—As previously described(16), echocardiographic images were
obtained in 1989–1990 and 1994–1995, using a standardized protocol with core reading
centers. The following measurements were examined without knowledge of thyroid status; left
ventricular (LV) mass and fractional shortening at the midwall, a quantitative measurement of
global chamber function, were calculated, as reported(17). Qualitative assessment of LV
ejection fraction (LVEF) was classified as normal, borderline, or abnormal, approximately
corresponding to values ≥55%, ≥45% and <45%, respectively(17). Agreement between
baseline and 5-year follow-up echocardiography core centers has been previously reported
(17). For diastolic function, left atrial size, Doppler peak E and A velocities were measured
(18,19). Doppler filling velocities and their ratios, consistent with impaired relaxation and
restrictive filling, were previously found in CHS to be predictive of incident HF(14). 896
participants had missing 1994–1995 echocardiograms, because of death (36%), missed visit
(17%) or follow-up visit outside the clinics with no echocardiogram (47%). The 576 alive
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participants without follow-up echocardiograms were older, more likely to be nonwhite,
smoker, have diabetes, atrial fibrillation and subclinical hyperthyroidism (2.9 vs. 1.4%);
prevalence of hypertension, CVD, subclinical hypothyroidism and gender proportions did not
differ significantly. LVEF at the time of incident HF was based on data abstracted from reports
of echocardiograms performed during hospitalization for HF, and was classified as described
above.
Covariates—We collected self-reported race and smoking status, classified as never, current,
or former. Thyroid medication use was assessed annually via medication bottle examination.
Physical examination included blood pressure, heart rate, and body mass index (BMI).
Hypertension was defined as self-report and use of anti-hypertensive medications, or blood
pressure ≥140/90 mmHg. Diabetes was defined as a fasting glucose ≥126 mg/dL (7.0 mmol/
L) or use of hypoglycemic medication. Atrial fibrillation at baseline was self-reported or
determined on ECG or Holter monitor(9). For prevalent HF at baseline, self-reports were
confirmed by physical examination or, if necessary, by a validation protocol that included
surveys of treating physicians or review of medical records(20). Prevalent CVD (defined as
coronary heart disease, stroke, or transient ischemic attack) was based on self-report, medical
record verification and use of selected drugs.
Statistical analysis
We calculated HF incidence per 1000 person-years of follow-up, and used log-rank tests to
compare Kaplan-Meier estimates of HF incidence across the four thyroid groups. We used Cox
proportional hazard models to examine associations between the four groups and HF. The
multivariate models adjusted for known clinical risk factors of HF in older adults(12,15,21,
22) that might be potential confounders in the relationship between subclinical thyroid disease
and HF. To check the sensitivity of our results to the selection of covariates, we assessed models
that excluded potential confounders with p-values >0.2 after adjustment, and obtained similar
results. We hypothesized some interactions a priori: the relationship between subclinical
thyroid disease and HF might differ by gender, prevalent CVD or thyroxine use during follow-
up. As previously(9), we first examined models in which follow-up was censored at the time
of first thyroxine use, as the main analysis. Because of interaction with thyroxine use, we also
used models in which baseline hazard was stratified by thyroxine use during follow-up as a
time-dependent covariate, and participants changed stratum when thyroxine use was initiated.
We graphically examined smooth estimates of hazard function for HF against TSH to examine
cut-points at which HF risk might be increased, as well as tabulation of event rates within
smaller TSH intervals, and used Schoenfeld residuals to check proportional hazards assumption
for thyroid status and for covariates included in the multivariate models. We used models with
baseline hazard jointly stratified by four variables (prevalent atrial fibrillation, CVD, diabetes
and hypertension) that did not meet this assumption(23). We also categorized age, the only
continuous covariate that did not meet the assumption of log-linearity. Results were reported
as hazard ratios (HR), with 95% confidence intervals (CI).
Among participants with echocardiographic data, multiple linear regression was used to assess
baseline differences and changes over time in echocardiographic measurements across thyroid
groups, after adjustment for age and gender, similar to previous analyses of echocardiograms
in CHS(14). We conducted analyses using Stata 9.2 (Stata Corporation, Texas).
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Results
Baseline characteristics
The mean age was 72.6 years; 60% were women (Table 1). Mild subclinical hypothyroidism
(TSH 4.5–9.9 mU/L) was present in 428 (14.5%) participants, severe subclinical
hypothryoidism (TSH 10.0–19.9 mU/L) in 46 (1.5%), and subclinical hyperthyroidism in 44
(1.4%). Subclinical hypothyroidism was more common in women, and associated with lower
systolic blood pressure. Subclinical hyperthyroidism was associated with higher BMI and
lower LDL-cholesterol.
Baseline Echocardiographic Data
Most echocardiographic measurements at baseline did not differ significantly by thyroid status
(Table 2). Participants with TSH≥10.0 had a higher peak E velocity (0.80 vs 0.72 m/sec,
p=0.002), and this difference persisted after adjustment for age, gender, heart rate and systolic
blood pressure. Peak E velocity was associated with incident HF in the overall study sample
(HR 1.14 for each 0.1 m/sec increment, 95%CI:1.09–1.18, p<0.001) and in those with
TSH≥10.0 (HR 1.45, 95%CI:1.20–1.76, p<0.001) after adjustment for age, gender and systolic
blood pressure. Compared to euthyroidism, subclinical hyperthyroidism was associated with
larger left atrial size, higher proportions with E/A ratio <0.7, and increased heart rate (Table
2), differences that persisted after excluding those with atrial fibrillation.
Risk of Heart Failure Events
Over a median (interquartile range) follow-up of 12 years (7.0–14.4), 736 (24%) participants
developed HF events. Among the 474 participants with sublinical hypothyroidism, 109
received thyroxine replacement during follow-up, with 28 reporting intermittent use. Among
the 46 participants with TSH≥10.0, 22 received thyroxine during follow-up (7 intermittent
use). In the analysis censoring follow-up at first thyroxine use, participants with TSH≥10.0
had a greater incidence of HF compared to euthyroid participants (41.7 vs. 22.9/1000 person-
years, p=0.01), but rates were similar for those with subclinical hyperthyroidism or TSH 4.5–
9.9 (Figure). In multivariate analysis censoring at first thyroxine use, the risk of HF was
increased among those with TSH≥10.0 (HR: 1.88, 95%CI: 1.05–3.34; Table 3, model 1).
Multivariate model omitting lipids yielded similar results.
The relationship between subclinical hypothyroidsim and HF differed by thyroxine use during
follow-up (p=0.02 for interaction). In a model (model 2) including all follow-up and thyroxine
use as a time-dependent covariate, participants with TSH≥10.0 had an increased risk of HF
during periods where thyroxine use was not reported, but no increased risk during periods of
thyroxine use. Almost identical results were obtained using a model that incorporated history
of thyroxine use as a time-dependent covariate (participants classified as user from first use)
and allowing for interaction of this measure with thyroid status (data not shown).
Stratifying sublinical hypothyroidism into those with TSH 4.5–6.9 and 7.0–9.9 mU/L, we
similarly found no significantly increased risk of HF; graphical examination of hazard function
showed no increased risk up to around 10 mU/L. A cubic spline analysis also showed the non-
linearity of this relationship. None of the 6 participants with TSH<0.10 had HF events. The
relationship between subclinical thyroid disease and HF did not differ by prevalent CVD or
gender (each interaction p value >0.20). Excluding 595 participants with prevalent CVD
yielded similar results, including in those with TSH≥10.0 (HR: 2.17, 95%CI: 1.15–4.07) in
multivariate analysis censoring at first thyroxine use. Based on baseline echocardiographic
data, peak E velocity might be a potential mediator of this relationship; further adjusting Model
1 for peak E velocity yielded an HR of 1.69 (95%CI: 0.94–3.02) for those with TSH≥10,
showing that this relationship was not fully explained by increased peak E velocity and that
Rodondi et al. Page 5
J Am Coll Cardiol. Author manuscript; available in PMC 2010 May 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
other factors, including unmeasured echocardiographic parameters, might play a role in this
relationship.
Echocardiographic Changes over Time
Repeat echocardiograms were obtained on 2148 participants after 5 years; those with
TSH≥10.0 had a larger increase in LV mass (+21 vs. +4 g, p=0.04, Table 4) and a greater
proportion of HF events associated with low EF than in euthyroid participants (80 vs. 45%,
p=0.08). Peak E velocity decreased more in subjects with TSH≥10 than in euthyroid
participants (−0.10 vs. −0.01m/sec, p=0.005), which might be related to increase in LV mass
over time, increasing impairment of LV relaxation, a plateau effect and/or regression to the
mean due to higher baseline values.
Compared to euthyroidism, subclinical hyperthyroidism was associated with a smaller increase
in left atrial size and peak A velocity over time, but cross-sectional year-5 left atrial sizes and
peak A velocities did not differ (40.5 vs. 40.0 mm, p=0.65; 0.81 vs. 0.81 m/sec, p=0.90).
Excluding participants with atrial fibrillation at baseline or those who developed HF before
year 5 examination (n=237) yielded similar results. For the 499 participants who developed
HF after year 5 examination, the time interval±SD between the 5-year echocardiograms and
HF was 4.4±2.6 years (3.5±1.9 for those with TSH 10.0).
Discussion
In this large, population-based study of older adults, subclinical hypothyroidism was associated
with a moderately elevated risk of HF among older adults with TSH≥10.0 mU/L, consistent
with another large cohort study of older individuals(10). The risk of CHF was not increased
among the high proportions of older adults with TSH levels between 4.5 and 9.9 mU/L or
among those with TSH<0.45. Adverse alterations in two echocardiographic measurements,
peak E velocity at baseline - an echocardiographic measurement of diastolic function associated
with HF in this cohort sample and previous CHS analysis(14) - and increase in left ventricular
mass over 5 years, were also found exclusively in the subgroup of subclinical hypothyroidism
with TSH≥10.0 mU/L.
To our knowledge, only one previous population-based prospective study directly examined
the relationship between subclinical hypothyroidism and HF events, and found that adults aged
70–79 with TSH≥7.0 mU/L had a higher risk of HF (HR: 2.88, 95%CI 1.39–5.99) in
multivariate analysis compared to euthyroid participants, with a more pronounced risk in those
with TSH≥10 (HR 3.10, 95%CI: 1.30–7.39), and no increased risk in those with TSH 4.5–6.9
(10). Possible explanations for the weaker point estimate found in CHS as compared to the
Health, Aging, and Body Composition (Health ABC) Study include differences in the study
population that was mainly white in CHS (40% were black in Health ABC), younger mean age
(72.6 vs. 74.7), different length of follow-up (12 vs. 4 years), no upper TSH cut-off in Health
ABC analysis (1% with TSH≥20) and less precision due to lower power in the Health ABC.
In the present study, the fact that HF risk was limited to participants with TSH≥10 who were
not taking thyroxine, with a HF risk similar to the euthyroid group under thyroxine replacement,
strengthens the case for a potential causal relationship, which could only be definitively proven
by RCTs. Potential mechanisms for the impact of thyroid dysfunction on HF may be related
to the effects of thyroid hormones on the heart(5,7), notably by the regulation of genes coding
for cardiac proteins(5). Overt hypothyroidism also alters cardiovascular function(24).
For most echocardiographic measurements, we found no significant differences for subclinical
hypothyroidism or hyperthyroidism compared to euthyroidism, in contrast to several non
population-based studies(6,25–27), but consistent with other population-based studies(28,
29). Several explanations exist for these discrepant findings, including the age of the underlying
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study population and the degree of subclinical thyroid dysfunction(8). All of these previous
studies had insufficient sample sizes with subclinical hypothyroidism (n=8–66 as compared to
474 in the present study) to investigate different TSH cutoffs(7,28), and none linked
abnormalities in the surrogate echocardiographic markers with HF events(8). Indeed, our
participants with subclinical hyperthyroidism demonstrated some differences in baseline
echocardiographic measurements, but no increase in HF events, suggesting that these
echocardiographic abnormalities, while statistically significant, do not result in HF. In our
cohort, those with TSH≥10.0 had a higher peak E velocity at baseline, an echocardiographic
measurement of diastolic function that was associated with incident HF in this cohort sample
and previous CHS analysis(14). The higher early diastolic filling velocity we found in
participants with TSH≥10 may reflect increased left atrial pressure and diastolic dysfunction
from more marked subclinical hypothyroidism. Some small RCTs have been performed that
have shown improvement in echocardiographic measures of cardiac function(30–32),
supporting our findings of reduction of risk of HF after thyroxine initiation.
Limitations and Strengths
Among limitations, our data may not be generalizable to younger age groups and it has been
suggested that there may be age differences in the associations between subclinical thyroid
dysfunction and adverse outcomes(33). Thyroid function testing was performed at a single
point in time, which is a limitation of all published observational cohorts(10,11,34). Our power
was limited in those with TSH≥10, as this group was small. Our echocardiographic findings
could be affected by multiple comparisons and missing data for 5-year and incident HF
echocardiograms; we could not definitively conclude on the type of cardiac dysfunction
(systolic or diastolic) involved in those with TSH≥10, which needs to be explored in future
studies.
These data have a number of strengths: the large, population-based cohort of older adults,
designed to examine cardiovascular risk factors; the mean 12-year follow-up; the formal
adjudication of HF events; the exclusion of individuals taking thyroxine or other medications
that could affect thyroid function testing; and the incorporation of thyroxine use over time
analytically(9). In addition, few large prospective studies have the availability of baseline and
follow-up echocardiography data.
Clinical Implications
Our data suggest that subclinical hypothyroidism with a TSH≥10.0 mU/L represents a
potentially modifiable risk factor for HF in older adults, but not subclinical hypothyroidism
with moderate TSH levels (TSH 4.5–9.9 mU/L) and subclinical hyperthyroidism. Our study
builds on the prior study demonstrating increased HF risk in marked subclinical
hypothyroidism(10), with additional mechanistic support in our study from echocardiographic
data and information on reversibility of HF risk with thyroxine replacement. Our findings of
a lack of HF risk in the high proportions of older adults with less severe subclinical
hypothyroidism are also important, as many patients with TSH levels of 4.5–9.9 mU/L are
treated in clinical practice(35), without consistent evidence to support increased risk without
thyroxine replacement and improved risk with replacement(1,3). This and previous studies
have mostly found no increased cardiovascular risk in subjects with TSH<10(9,10,36), with
some conflicting data(11). Moreover, about 20 % of patients are currently overtreated by
thyroxine replacement with an increased risk of subclinical hyperthyroidism that has been
associated with atrial fibrillation and increased fracture risk(3,37). In aggregate, our findings
might help refine a treatment threshold at which clinical benefit would be expected(8) and
demonstrate a subpopulation at risk for a life-threatening condition. Clinical trials should
examine the efficacy of screening for and treating subclinical thyroid dysfunction, and assess
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whether the risk of HF might be ameliorated by thyroxine replacement in individuals with TSH
levels above 10.0 mU/L.
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Figure. Incident Heart Failure Events According to TSH Levels
Abbreviations: TSH: thyroid-stimulating hormone.
Participants with TSH≥10.0–19.9 mU/L who were untreated by thyroxine replacement
(participants censored at the time of first thyroxine use) had a greater incidence of HF events
compared to euthyroid participants (41.7 vs. 22.9/1000 person-years, p=0.01), but rates were
similar for those with subclinical hyperthyroidism or those with TSH between 4.5 and 9.9 mU/
L.
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Table 2
Echocardiographic characteristics at baseline according to thyroid status *
Measure (n) Subclinical Hyperthyroid Euthyroid Subclinical Hypothyroid
TSH categories, mU/L TSH < 0.45 (n=44) TSH 0.45–4.5 (n=2526) TSH 4.5–9.9 (n=428) TSH 10.0–19.9 (n=46)
Systolic function
LV ejection fraction, qualitative
assessment (3020)
 Normal (≥55%), % 88.1 93.4 91.0 93.5
 Borderline (<55%), % 9.5 4.5 5.2 6.5
 Abnormal (<45%), % 2.4 2.2 3.8† 0
LV mass, g (2031) 149 ± 58 149 ± 48 144 ± 45 146 ± 42
Fractional shortening at the
midwall, % (2006)
43.3 ± 10.1 42.2 ± 8.1 42.5 ± 7.9 43.1 ± 7.8
Diastolic function
Left atrial dimension, mm (2947) 40.7 ± 6.4† 38.6 ± 6.6 38.5 ± 6.7 39.5 ± 6.5
Peak E, m/sec (2951) 0.72 ± 0.18 0.72 ± 0.18 0.72 ± 0.20 0.80 ± 0.25††‡
Peak A, m/sec (2951) 0.85 ± 0.29 0.79 ± 0.22 0.79 ± 0.23 0.83 ± 0.26
E/A ratio (2951)§ 0.81 [0.68–0.98] 0.89 [0.74–1.07] 0.90 [0.75–1.08] 0.92 [0.82–1.13]
 <0.7: impaired relaxation, % 35.7†† 17.4 16.1 13.0
 0.7–1.5, % 59.5 77.0 78.1 82.6
 >1.5: restrictive filling pattern,
%
4.8 5.6 5.8 4.4
Other measurements
Heart rate, sec (3034) 69 ± 11† 64 ± 10 65 ± 10 64 ± 7
Abbreviations: TSH: thyroid-stimulating hormone, LV = left ventricular, Peak E = doppler early diastolic peak filling velocity, Peak A = doppler late
diastolic peak filling velocity, E/A ratio = early/late transmitral peak flow velocity ratio. E/A ratio was used to categorize impaired relaxation (low E/
A) and restrictive patterns (high E/A).
*
Values are mean ± SD or percentages. For each outcome measure, those for whom the outcome measure was not available were not included in the
analysis.
†
P <0.05,
††
p < 0.01 compared to euthyroid category, after adjustment for age and gender. No significant differences for other comparisons. For mitral filling
velocities, differences were similar after further adjustment for heart rate and systolic blood pressure.
‡
P = 0.008 according to Kruskal-Wallis test.
§
Expressed as median [25%–75%], and reciprocal transformation of the variable (1/x) to normalize the distribution for adjusted comparisons.
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